103 related articles for article (PubMed ID: 10789551)
1. Effects of subinhibitory concentrations of moxifloxacin in an in-vitro dynamic model.
Maggiolo F; Capra R; Bartoli A; Bottura P; Migliorino M; Suter F
J Chemother; 2000 Apr; 12(2):129-33. PubMed ID: 10789551
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
3. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.
Odenholt-Tornqvist I; Löwdin E; Cars O
Antimicrob Agents Chemother; 1992 Sep; 36(9):1852-8. PubMed ID: 1329631
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal properties of moxifloxacin and post-antibiotic effect.
Boswell FJ; Andrews JM; Wise R; Dalhoff A
J Antimicrob Chemother; 1999 May; 43 Suppl B():43-9. PubMed ID: 10382875
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.
Licata L; Smith CE; Goldschmidt RM; Barrett JF; Frosco M
Antimicrob Agents Chemother; 1997 May; 41(5):950-5. PubMed ID: 9145850
[TBL] [Abstract][Full Text] [Related]
6. Calculation of composite recovery time: a new pharmacodynamic parameter.
MacKenzie FM; Milne KE; Gould IM
J Antimicrob Chemother; 2002 Aug; 50(2):281-4. PubMed ID: 12161413
[TBL] [Abstract][Full Text] [Related]
7. Gepotidacin (GSK2140944)
Flamm RK; Farrell DJ; Rhomberg PR; Scangarella-Oman NE; Sader HS
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483959
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic effects of subinhibitory concentrations of imipenem on Pseudomonas aeruginosa in an in vitro dynamic model.
Maggiolo F; Taras A; Frontespezi S; Legnani MC; Silanos MA; Pravettoni G; Suter F
Antimicrob Agents Chemother; 1994 Jun; 38(6):1416-8. PubMed ID: 8092847
[TBL] [Abstract][Full Text] [Related]
9. The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Rubinstein E; Diamantstein L; Yoseph G; Gruzman G; Rubinovitch B; Barzilai A; Keller N
Clin Microbiol Infect; 2000 Dec; 6(12):678-81. PubMed ID: 11284929
[No Abstract] [Full Text] [Related]
10. Postantibiotic effect, and postantibiotic effect of subinhibitory concentrations, of sparfloxacin on gram-negative bacteria.
Odenholt-Tornqvist I; Bengtsson S
Chemotherapy; 1994; 40(1):30-6. PubMed ID: 8306813
[TBL] [Abstract][Full Text] [Related]
11. Postantibiotic effects and postantibiotic sub-MIC effects of amoxicillin on Streptococcus gordonii and Streptococcus sanguis.
Lee SY
J Chemother; 2000 Oct; 12(5):379-84. PubMed ID: 11128556
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
Piddock LJ; Jin YF
J Antimicrob Chemother; 1999 May; 43 Suppl B():39-42. PubMed ID: 10382874
[TBL] [Abstract][Full Text] [Related]
13. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
[TBL] [Abstract][Full Text] [Related]
15. Postantibiotic effect and postantibiotic sub-minimum inhibitory concentration effect of valnemulin against Staphylococcus aureus isolates from swine and chickens.
Zhao DH; Yu Y; Zhou YF; Shi W; Deng H; Liu YH
Lett Appl Microbiol; 2014 Feb; 58(2):150-5. PubMed ID: 24117872
[TBL] [Abstract][Full Text] [Related]
16. Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.
Odenholt I; Löwdin E; Cars O
Antimicrob Agents Chemother; 2003 Oct; 47(10):3352-6. PubMed ID: 14506057
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.
Lemmen SW; Häfner H; Klik S; Lütticken R; Zolldann D
Chemotherapy; 2003 May; 49(1-2):33-5. PubMed ID: 12714807
[TBL] [Abstract][Full Text] [Related]
18. Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G.
MacGowan AP; Bowker KE; Wootton M; Holt HA
J Antimicrob Chemother; 1999 Dec; 44(6):761-6. PubMed ID: 10590276
[TBL] [Abstract][Full Text] [Related]
19. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.
MacGowan A; Rogers C; Holt HA; Wootton M; Bowker K
J Antimicrob Chemother; 2000 Jul; 46(1):73-8. PubMed ID: 10882692
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
Lister PD
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S33-8. PubMed ID: 11249827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
